Thursday, June 21, 2018 3:27:32 PM
"Item 7.01 Regulation FD Disclosure.
On June 21, 2018, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from its Phase 2b study of HTX-011 in subjects undergoing total knee arthroplasty and breast augmentation, as described in the press release furnished herewith as Exhibit 99.1.
The Company also issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to the Company’s investigational agent, HTX-011, for postoperative pain management, as described in the press release furnished herewith as Exhibit 99.2.
A copy of presentation materials describing a Company update, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished as Exhibit 99.3 hereto. The attached materials have also been posted on the Company’s website at www.herontx.com . The Company does not undertake any obligation to update this presentation.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated June 21, 2018
99.2 Press Release, dated June 21, 2018
99.3 Corporate Presentation, dated June 21, 2018"
**********************************
"About HTX-011 for Postoperative Pain
HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. HTX-011 has been shown to reduce pain significantly better than placebo or bupivacaine alone in five diverse surgical models: hernia repair, abdominoplasty, bunionectomy, total knee arthroplasty and breast augmentation. HTX-011 was granted Fast Track designation from the FDA in the fourth quarter of 2017 and Breakthrough Therapy designation in the second quarter of 2018. In the second half of 2018, Heron expects to submit a New Drug Application (NDA) to the FDA for HTX-011."
Recent HRTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:05:13 PM
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • PR Newswire (US) • 04/24/2024 12:00:00 PM
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City • PR Newswire (US) • 04/11/2024 08:05:00 PM
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Biotech Finds Mid-Week Success Following Q4 Earnings Release • AllPennyStocks.com • 03/13/2024 08:25:00 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Global Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market Trading • IH Market News • 03/12/2024 11:22:57 AM
- Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 • PR Newswire (US) • 02/28/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:37:34 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:21:51 PM
- Premarket Heats Up For Biotech Before Opening Bell • AllPennyStocks.com • 01/24/2024 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 01:01:00 PM
- Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures • PR Newswire (US) • 01/24/2024 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:05:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:04:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:04:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:03:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:02:44 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM